The Claim
Insulin and niacin do not significantly activate the ERK1/2 MAP kinase pathway in human subcutaneous adipose tissue under the conditions tested, suggesting this pathway is not a major mediator of free fatty acid uptake in vivo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In human fat tissue, neither insulin nor niacin strongly triggers the ERK1/2 signaling pathway under the conditions studied, indicating that this pathway likely does not play a major role in how free fatty acids are taken up by fat cells in the body.
See the scientific wording
Insulin and niacin do not significantly activate the ERK1/2 MAP kinase pathway in human subcutaneous adipose tissue under the conditions tested, suggesting this pathway is not a major mediator of free fatty acid uptake in vivo.
When niacin or insulin is given, they both stop fat cells from releasing fatty acids into the blood. This lets more fatty acids stay inside the fat tissue, even though only insulin turns on a specific signaling pathway called ERK1/2. Since both drugs cause the same amount of fat storage, the ERK1/2 pathway isn’t needed for this to happen.
What the research says
1 studyThe study found that insulin and niacin both led to the same amount of fat storage in fat tissue, even though they work differently in the body. Since niacin doesn’t activate a certain signaling pathway (ERK1/2), but insulin does, and both had the same effect, this suggests that pathway isn’t important for fat storage.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.